|
Azacitidine in the management of patients with myelodysplastic syndromes.
|
Dec 2012
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations
|
Aug 2016
|
Ther Clin Risk Manag
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
|
Sep 2019
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study
|
Oct 2020
|
Therapeutic Advances in Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
|
Jan 2021
|
Therapeutic Advances in Hematology
|
myelodysplastic syndromes (MDS)
|
|
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
|
May 2019
|
Therapeutic Advances in Hematology
|
myelodysplastic syndromes (MDS)
|
|
The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria
|
Jul 2016
|
Thromb Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Aplastic anemia and risk of deep vein thrombosis and pulmonary embolism: A nationwide cohort study
|
Jan 2017
|
Thromb Res
|
aplastic anemia
|
|
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
|
Feb 2014
|
Transl Med UniSa
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Immunological derangement in hypocellular myelodysplastic syndromes
|
Feb 2014
|
Transl Med UniSa
|
myelodysplastic syndromes (MDS)
|
